Set menu
AIM:
Total number of AIM Companies (Incl Susp):
919*
Total number of AIM Companies trading:
844*
*as at close of business 31 December 2018
Standard List** of Main Market:
Total number of Standard List Companies
(Incl Susp):
139*
Total number of Standard List Companies trading:
130*
*as at close of business 31 December 2018
NEX Growth Market:
Total number of NEX Growth Market Companies (Incl Susp):
89*
Total number of NEX Growth Market Companies trading:
87*
*as at close of business 31 December 2018
*A corporate client of Hybridan LLP
** Standard Listing as defined by Hybridan LLP to be a business with strictly operational activity
Dish of the day
No Joiners today
Off the menu
No Leavers Today
What’s cooking in the IPO kitchen?
Main Market (Specialist Funds)
The Global Sustainability Trust -aiming for attractive risk-adjusted returns by investing primarily in private market investments that are expected to have a positive environmental and social impact raising c.£200m. Due 31 Jan 2019.
AIM
Greenfields Petroleum (TSX-V:GNF) production focused company with operated assets in Azerbaijan seeking AIM dual listing including $60m private placement. Mkt cap $12.6m CAD. Expected late January 2019.
Banquet Buffet
Mattioli Woods (LON:MTW) 660p £174m
HYNov18 trading update from the specialist wealth management and employee benefits business.
EBITDA margin in first half substantially ahead of 20% target
Total client assets at the period end of £8.8bn
Gross discretionary assets under management of £2.4bn
Recent acquisitions performing and integrating well
Strong financial position, with cash of over £16m
Profit outlook for year in line with management's expectations
Physiomics* (LON:PYC) 3.85p £2.77m
Physiomics will be attending the Biotech Showcase partnering conference in San Francisco from 7-9 Jan 2019 during the JP Morgan Healthcare Conference week. During this week, many of the world's most successful biotech and pharmaceutical companies are present in San Francisco to meet with prospective clients and partners. Over three thousand attendees are expected to participate in over seven thousand organised 1-1 meetings. Physiomics has confirmed meetings with oncology companies from around the world interested in finding out more about our Virtual Tumour platform and how it can enhance their drug discovery and development programs.
Medaphor (LON:MED) 7.75p £12.14m
The “intelligent ultrasound software and simulation company, announces that Group turnover for the year to 31 Dec 2018, which was generated entirely by the Group's Simulation Division, is expected to grow by approximately 27% to between £5.3m and £5.4m (2017: £4.2m). The pre-exceptionals EBITDA loss for the year is expected to be around £3m (2017: Loss, £1.7m). This includes approximately £1.5m of primarily R&D expenses attributable to investment in the Group's Clinical Artificial Intelligence Division which was established with the acquisition of Intelligent Ultrasound Limited ("IUL") on 6 Oct 2017 (3 months to 31 Dec 2017, IUL overheads: £0.2m). Group management, PLC costs and share-based payment charges included in the adjusted loss are expected to be £0.9m (2017: £0.8m).”
Eagle Eye Solutions Group (LON:EYE) 96.7p £24.6m
The SaaS technology company that allows businesses to create a real-time connection with their customers through digital promotion and loyalty services, announced a new five-year contract with Waitrose Limited.
The employee owned British supermarket chain will be taking advantage of Eagle Eye's AIR platform to improve their digital marketing proposition.
This contract signing extends Eagle Eye's existing relationship with John Lewis Plc that was first announced in May 2017, enabling the platform to connect to all customers across the group.
The Company continues to trade in-line with the Board's expectations.
Anglo African Oil and Gas (LON:AAOG) 16.55p £29.45m
Schlumberger wireline logging completed on the TLP-103C well has confirmed multiple discoveries at its Tilapia licence in the Republic of the Congo. Wireline logging validates the initial results identified during drilling the targeted R1/R2/R3 and the Mengo reservoirs and confirms oil columns amounting to an aggregate of 44 metres across the identified horizons.
26 metre oil column in the Mengo identified in sandstones interbedded with claystones between 1874,8mMD and 1900,8mMD
An aggregate 13 metres of oil columns across the new horizons identified between the R3 and the Mengo horizons in three layers of sandstones between 1473mMD and 1685,5mMD
5 metre oil column identified in the R2 reservoir between 1282,7mMD and 1287,7mMD in line with the TLP-101V well located in fine sandstones
Modular formation dynamics tests showed that the R2 reservoir is not depleted, confirming an onshore hydrocarbon system underlying the Tilapia licence area.
Mpac Group (LON:MPAC) 109p £21.99m
The “global leader in 'Make, Pack, Test and Service' high speed packaging solutions, provides a pre-close trading update for the year ended 31 Dec 2018.
We are pleased to report that sales growth continued in the second half of the year. We also launched a number of new product innovations at the Chicago Pack Expo trade show which were well received by customers and resulted in new contract wins. During the second half we also secured a number of contracts for delivery in 2019.
Considerable progress has been made in delivering on the Group's strategic priorities and in resolving the two technically challenging legacy contracts. The UK legacy contract has been resolved and we have agreed the commercial approach to resolving the Canadian contract which is expected to be finalised during 2019.
Also announced that sales and profit before tax are expected to be in line with market expectations (subject to year end audit), supported by a strong closing orderbook which will provide a platform for continued growth in 2019.”
FYDec18E rev £57m and PBT £1.35m.
Nektan (LON:NKTN) 14p £6.6m
“The fast growing international gaming technology platform and services provider, announced another record quarter for the second three months of the financial year ending 30 June 2019”.
Total Gaming Revenue increased 28.4% to £8.6m in Q2 FY19, up from £6.7m in Q1 FY19 (up 83% on Q2 FY18).
In Q2 FY19 Nektan's technology generated over £222.5m in Cash Wagers, up from £182.4m in Q1 FY19, representing an increase of £40.1m (22% growth).
Growth driven by a significant increase in the number of unique players on the B2B platform, helped by 4 new partners going live.
Premium gaming content added across both B2C and B2B divisions.
Additional partners signed up across both B2C and B2B divisions, including BetVictor in B2B.
Growth trajectory should result in European EBITDA break-even by the end of FY19 (30 June 2019).
RedEmperor (LON:RMP) 3.5p £14.89m
The “natural resource exploration company, provided a further operational update with respect to preparations for the drilling of the Winx-1 exploration well, located on the Western Blocks, North Slope of Alaska.
Ice road construction for the Winx-1 exploration well has commenced
Winx-1 Permit to Drill submitted on schedule
Spud of the Winx-1 exploration well on schedule for mid-late February 2019”
4D pharma (LON:DDDD) 107.75p £70.57m
The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to evaluate 4D's Live Biotherapeutic oncology pipeline across a range of cancer settings.
The alliance brings together MD Anderson's translational medicine and clinical research capabilities with 4D's expertise in the discovery and development of Live Biotherapeutics. The collaboration will initially assess 4D's lead oncology candidate, MRx0518, as a potential treatment for solid tumours.
The first clinical study, an open label Phase I study of MRx0518 in combination with Keytruda® and conducted in collaboration with Merck & Co., Inc., Kenilworth, NJ., USA, has been initiated and is due to open shortly. The study will enrol up to 132 patients with metastatic cancer across multiple histologies (non-small cell lung cancer, renal cell carcinoma, bladder cancer and melanoma) who have failed prior anti-PD-1 therapy.